Recombinant Human Anti-HIV-1 Antibody (1281) (CAT#: PABX-001)

Figure 1 Neutralization of HIV-1₈₉.₆ by anti-gp41 MAbs.

The percent neutralization of HIV-1₈₉.₆, shown on the y axis, was determined with increasing amounts of anti-gp41 MAbs (x axis) or with an anti-parvovirus MAb, 860-55D, used as a negative control. The GHOST cell neutralization assay was used, and the results are represented as the mean of two or three separate experiments for each MAb.

Verrier, F., Nádas, A., Gorny, M. K., & Zolla-Pazner, S. (2001). Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. Journal of Virology, 75(19), 9177-9186.

Figure 2 Anti-HIV-1 gp41 cluster II antibodies preferentially bind gp41 in its postfusion conformation.

Human anti-gp41 cluster II mAbs, 1281, 98-6D, 126-7D, 167D and 1379, were analyzed by a surface plasmon resonance (SPR) assay for binding to HIV-1 gp41 constructs: gp140 (sensorgrams in black); GNC4-gp41-inter (blue); and gp41-post (red). GCN4-gp41-inter or gp41-post was immobilized on CM5 chips; gp140 was captured on a Ni-NTA chip. Each IgG at 50 nM was passed over each surface individually.

Frey, G., Chen, J., Rits-Volloch, S., Freeman, M. M., Zolla-Pazner, S., & Chen, B. (2010). Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nature structural & molecular biology, 17(12), 1486.